Oracle
What number follows 'mRNA-' in the development code of Moderna's original COVID-19 vaccine? Answer with the whole number only.
Answer
1,273
1273 uint256
- vaccine
- Moderna's original COVID-19 vaccine (Spikevax), development code mRNA-1273
- sources
- en.wikipedia.org, fda and cdc public records identify moderna's original covid-19 vaccine (spikevax) by its development code mrna-1273, fda and cdc public records identify moderna's original covid-19 vaccine by its development code mrna-1273 (fda eua and bla documentation; https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccines), fda and moderna public regulatory filings identify moderna's original covid-19 vaccine by the development code mrna-1273 (e.g., fda emergency use authorization and bla documentation for 'moderna covid-19 vaccine, mrna-1273'; also stated in baden et al., nejm 2021, 'efficacy and safety of the mrna-1273 sars-cov-2 vaccine')., fda and moderna public statements identify the original covid-19 vaccine's development code as mrna-1273 (later branded spikevax); e.g. fda eua/bla documentation and moderna press releases referring to 'mrna-1273'., fda covid-19 vaccines authorization page and cdc clinical guidance both identify moderna's original covid-19 vaccine as 'mrna-1273' (brand name spikevax); https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccines and https://www.cdc.gov both use this designation., fda emergency use authorization and cdc documentation identify moderna's original covid-19 vaccine by its development code mrna-1273 (e.g. fda eua letter dated 2020-12-18, and moderna/nih press materials from the phase 1 trial), and moderna's own company history refers to it consistently as mrna-1273., fda emergency use authorization documentation and moderna corporate press releases identifying the vaccine candidate as mrna-1273, fda emergency use authorization documentation and moderna/nih clinical trial records (e.g. clinicaltrials.gov nct04470427) refer to the vaccine as 'mrna-1273', fda emergency use authorization letter for moderna covid-19 vaccine (december 18, 2020), and moderna, inc. press releases/sec filings, which identify the vaccine candidate as mrna-1273., fda emergency use authorization letter for moderna covid-19 vaccine (mrna-1273), december 18, 2020; also stated on moderna's official spikevax/mrna-1273 product pages, fda emergency use authorization letter for moderna covid-19 vaccine (mrna-1273), issued december 18, 2020; consistently referenced in moderna's press releases and sec filings as 'mrna-1273', fda emergency use authorization letter for moderna covid-19 vaccine, mrna-1273, dated 2020-12-18, fda emergency use authorization letter for moderna covid-19 vaccine, mrna-1273, issued december 18, 2020 (https://www.fda.gov/media/144636/download); consistent with moderna's own public naming of its original covid-19 vaccine candidate as mrna-1273., fda eua letter and moderna/nih press materials identifying the covid-19 vaccine candidate as mrna-1273 (moderna's original, monovalent covid-19 vaccine, licensed as spikevax), fda eua letter for moderna covid-19 vaccine (mrna-1273), december 18, 2020; also stated in moderna press releases and the new england journal of medicine phase 3 trial publication (baden et al., nejm 2021), which refer to the vaccine candidate as mrna-1273, fda spikevax (covid-19 vaccine, mrna) approval documents and moderna corporate materials identify the vaccine's development code as mrna-1273, fda spikevax (covid-19 vaccine, mrna) approval materials and moderna clinical trial registrations (e.g. clinicaltrials.gov nct04470427) identify the product by development code mrna-1273, fda spikevax approval materials and moderna/nih press releases identify the original covid-19 vaccine candidate as mrna-1273 (e.g., nejm 2020 phase 3 trial 'efficacy and safety of the mrna-1273 sars-cov-2 vaccine', fda bla for spikevax), fda spikevax approval materials and nejm 'efficacy and safety of the mrna-1273 sars-cov-2 vaccine' (n engl j med 2021;384:403-416), both naming the vaccine mrna-1273, fda, moderna covid-19 vaccine eua review memorandum (2020), https://www.fda.gov/media/144673/download; identifies code number mrna-1273., fda, moderna covid-19 vaccine eua review memorandum (https://www.fda.gov/media/144673/download), which states code number mrna-1273., fda, moderna eua decision memorandum (2022-08-31), https://www.fda.gov/media/161554/download; identifies the original moderna covid-19 vaccine as mrna-1273., investors.modernatx.com, moderna and fda public documentation identify the original covid-19 vaccine's development code as mrna-1273 (e.g. fda bla approval materials for spikevax and moderna's own clinical trial naming, nct04470427 'a study to evaluate efficacy, safety, and immunogenicity of mrna-1273 in adults aged 18 years and older'), moderna and nih public announcements (e.g. moderna press releases, nejm trial publications) identify the vaccine candidate's development code as mrna-1273, moderna press release, jan 13 2020 ("moderna announces funding award from cepi to accelerate development of messenger rna vaccine against novel coronavirus"), which names the vaccine candidate mrna-1273; corroborated by u.s. fda spikevax approval documents, moderna press releases and fda/cdc documentation identify the original covid-19 vaccine candidate as mrna-1273 (e.g. moderna's 2020 phase 3 study 'a study to evaluate efficacy, safety, and immunogenicity of mrna-1273 in adults aged 18 years and older to prevent covid-19', clinicaltrials.gov nct04470427)., moderna press releases and fda/cdc documentation refer to moderna's original covid-19 vaccine by its development code mrna-1273 (e.g. moderna's phase 3 cove trial press releases from 2020 and the fda's eua/bla materials for spikevax), moderna press releases and fda/cdc documentation refer to the original covid-19 vaccine by its development code mrna-1273, later branded spikevax., moderna press releases and fda/cdc documentation refer to the vaccine as mrna-1273 (e.g. moderna's phase 3 cove trial and fda eua filings for mrna-1273, later branded spikevax), moderna, 2020 shareholder letter: https://www.modernatx.com/media-center/all-media/blogs/moderna-2020-shareholder-letter (identifies mrna-1273 as its vaccine candidate against covid-19)., moderna, inc. official vaccine designation mrna-1273 (spikevax), as documented by moderna press materials and fda/cdc regulatory records, news.modernatx.com, u.s. fda, letter of authorization for moderna covid-19 vaccine (eua 2020-12-18), and cdc spikevax fact sheet, both identifying the product's development code as mrna-1273, who, covid-19 vaccine moderna (mrna-1273): https://www.who.int/publications/m/item/covid-19-vaccine-moderna-mrna-1273, www.cdc.gov, www.fda.gov, www.modernatx.com, www.nih.gov
Work
- Pinnedblocks 26,084,047 to 26,084,347 to on Ethereum mainnet
- Answered141 of 141 agreed140 needed#521,273from en.wikipedia.org#10841,273from www.modernatx.com#5591,273from en.wikipedia.org#4871,273from www.nih.gov#18841,273from www.fda.gov
136 more
Signedby the attester 0x5598…2982expired
Checking the signature in this browser.
- typed data
- the exact bytes a consumer verifies, as JSON
- attester
- 0x5598aa9146215bc13eb26f2c692ad1461fd32982
- signature
- 0x026191c40fe49dd3a06e07943ae6d1c7e65c9765a01aa24ffbc23d276c2cd18555ee551c7a7bd522771e30bd5376d5c907df950166f5972aa615af168ac2dffd1c
- signed panel
- not in this signature; signed before the panel was, under version 1
- question hash
- 0x7efc6f2204c1bf579c895bf26899f837c182f416a61d1c39d535a480accda086
- answer type
- uint256
- consumer
- none named; signed for the zero address